Psoriasis is a common chronic inflammatory, immune-mediated disease that predominantly affects the skin and joints. An estimated 100,000 people are affected in Scotland, of whom approximately 20,000 may also have psoriatic arthritis
Remit and target users
This guideline covers psoriasis and psoriatic arthritis in adults. It includes a care pathway describing the patient journey between primary and secondary care and the assessments and treatments undertaken at each stage including: diagnosis; monitoring; comorbidities; psychological well-being; topical, systemic and biologic therapies; phototherapy; and organisation of care, including nurse-led clinics. The guideline does not cover treatment in pregnancy or preconception, palmoplantar pustulosis, or management of chronic pain.
This guideline will be of particular interest to allied health professionals, clinical psychologists, dermatologists, general practitioners, health psychologists, medical physicists, nurses, occupational health professionals, patients and carers, pharmacists, and rheumatologists.
How this guideline was developed
This guideline was developed using a standard methodology based on a systematic review of the evidence. Further details can be found in SIGN 50: A Guideline Developer’s Handbook .
Keeping up to date
This guideline was issued in 2010 and will be considered for review in three years. The review history, and any updates to the guideline in the interim period, will be noted in the review report.
Current 3-7 years
Some recommendations may be out of date, declaration of interests governance may not be in line with current policy.
Full guideline (PDF)
Quick reference guide (PDF)
Register of Interests
Search narrative (PDF)
Copyright permission (PDF)
Contact us email@example.com
SIGN 121, October 2010
ISBN 978 1 905813 67 4
Register of Interest
A register of interest is not available for this guideline. In line with the SIGN Document Retention Schedule (24/07/2010), after publication of this guideline, hard copies of declarations of interest were held at the SIGN Executive offices for one year. The declarations of interest were then archived for a further three years before being destroyed along with other guideline related documents. This schedule has now been revised.